Levodopa treatment linked to 47% lower risk of developing ‘wet’ macular degeneration

It turns out the gold-standard treatment for Parkinson’s might be protecting more than just movement—it could be saving eyesight too. New research published this month suggests that Levodopa is significantly linked to a lower risk of developing neovascular Age-Related Macular Degeneration (AMD), the aggressive "wet" form of the condition that is a leading cause of blindness in older adults. For years, scientists have noticed a curious pattern: people with Parkinson’s seem to develop this specific type of vision loss less often than the general population. Now, a major study from the Sight Outcomes Research Collaborative (SOURCE) has put a number on it. Their data shows that people taking Levodopa had a massive 47% reduced likelihood of their early-stage macular degeneration progressing to the wet form over a five-year period. The reason for this protective effect appears to lie in the biology of the eye itself. While we typically think of dopamine as the brain’s movement chemical, the retina—the light-sensitive layer at the back of the eye—is also hungry for it. In a healthy eye, dopamine helps regulate blood vessel growth. The theory is that Levodopa, by boosting dopamine levels, essentially tells the eye’s cells to calm down and stop producing the "leaky" blood vessels that characterise wet AMD. Specifically, the drug seems to trigger a receptor (called GPR143) that puts the brakes on a protein known as VEGF. If you have ever known someone who gets painful injections into their eye for macular degeneration, they are getting anti-VEGF drugs. This study suggests that the oral medication many people with Parkinson’s already take might be doing a similar job from the inside out. There is good news for the "dry" form of the condition as well. Separate data from the same research wave indicates Levodopa might also reduce the risk of developing Geographic Atrophy—the advanced stage of dry AMD—by around 32%. This is not a suggestion to start taking Levodopa purely for eye health, but it is a fascinating example of drug repurposing. It highlights how a treatment we have used for decades can still surprise us with hidden benefits, potentially offering a new way to delay vision loss without a needle in sight.